Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001842952-25-000034
Filing Date
2025-04-04
Accepted
2025-04-04 16:04:15
Documents
19
Period of Report
2025-06-12

Document Format Files

Seq Description Document Type Size
1 PRE 14A cntx-20250404.htm   iXBRL PRE 14A 494042
6 cntx-20250404_g1.jpg GRAPHIC 12205
7 cntx-20250404_g2.jpg GRAPHIC 438528
8 cntx-20250404_g3.jpg GRAPHIC 195655
  Complete submission text file 0001842952-25-000034.txt   2330784

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cntx-20250404.xsd EX-101.SCH 2891
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cntx-20250404_def.xml EX-101.DEF 3486
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cntx-20250404_lab.xml EX-101.LAB 4124
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cntx-20250404_pre.xml EX-101.PRE 2543
21 EXTRACTED XBRL INSTANCE DOCUMENT cntx-20250404_htm.xml XML 18788
Mailing Address 2001 MARKET STREET SUITE 3915 UNIT #15 PHILADELPHIA PA 19103
Business Address 2001 MARKET STREET SUITE 3915 UNIT #15 PHILADELPHIA PA 19103 267-225-7416
Context Therapeutics Inc. (Filer) CIK: 0001842952 (see all company filings)

EIN.: 863738787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-40654 | Film No.: 25813917
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)